A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Age range
18 Years – 75 Years
Last updated September 2025